



## CALL FOR PUBLIC COMMENT

November 1, 2024

Dear Colleagues,

The ECMM and MSGERC have created 4 Collaborative Working Groups that have been re-defining fungal disease outcomes, as an update to previously published outcome criteria

We are pleased to invite you to provide comments to our near final draft for the ECMM/MSGERC Aspergillus and Mold Outcome Criteria Working Group, entitled:

**“Revised definitions of responses to therapy and study outcomes in clinical trials of aspergillosis and rare mould infections: Mycoses Study Group and European Confederation of Medical Mycology consensus criteria.”**

Many of the criteria are unchanged, but subtle changes are listed below:

- Patient and clinician important outcomes: Emphasizing the importance of clinical response versus radiological and mycological response.
- Proposed measurements for clinical and safety responses.
- Refined the differentiation between partial and stable response (success versus failure).
- Proposed solutions for assessing attributable mortality.
- Inclusion of paediatric input.
- Inclusion of FDA, EMA and stakeholder input from Listening Sessions.
- Inclusion of patient involvement in draft reviews.

### ACCESS:

The Aspergillus/Mold paper [here](#)

Review Supplement [here](#)

Password for each document: [ECMMMSGERCNov2024asp](#)

Please note, documents are not enabled for editing or downloading in this view. **At this juncture, we are soliciting public feedback.**

**You may send your feedback by email to [Headquarters@msgerc.org](mailto:Headquarters@msgerc.org). Please indicate “Aspergillus Feedback” in the subject of your email response. The documents will be viewable until November 30, 2024.**

Sincerely,

Martin Hönigl, MD  
ECMM Aspergillus/Mold Co-Chair

Monica Slavin, MD  
MSGERC Aspergillus/Mold Co-Chair